Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisFRA:EX9 +3.50%90 Return-on-Tangible-Asset is 34.26% as of Jun. 2026, which is 144% above its 10-year median of 14.04. GuruFocus rates FRA:EX9 with a GF Score™ of 90/100 and a GF Value™ of €40.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, Exelixis ranks better than 97.24% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Exelixis's annualizedNet Income for the quarter that ended in Jun. 2026 was €736 Mil. Exelixis's average total tangible assets for the quarter that ended in Jun. 2026 was €2,149 Mil. Therefore, Exelixis's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 34.26%.
The historical rank and industry rank for Exelixis's Return-on-Tangible-Asset or its related term are showing as below:
FRA:EX9'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -17.54 Med: 14.04 Max: 70.77
Current: 32.81
During the past 13 years, Exelixis's highest Return-on-Tangible-Asset was 70.77%. The lowest was -17.54%. And the median was 14.04%.
FRA:EX9's Return-on-Tangible-Asset is ranked better than 97.24% of 1415
companies
in the Biotechnology industry
Industry Median: -35.77
vs FRA:EX9: 32.81
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Exelixis Return-on-Tangible-Asset Related Terms
Exelixis Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Exelixis's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EX9 vs MDGL, AXSM, ARWR: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Exelixis's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Exelixis's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 34.26% mean?
Exelixis (FRA:EX9) has a Return-on-Tangible-Asset of 34.26% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Exelixis and its competitors. This is 144% above median its historical median of 14.04. According to the industry distribution chart, Exelixis ranks #39 out of 1415 companies in the Biotechnology industry, placing it in the top 2.8%.
Is Exelixis' Return-on-Tangible-Asset too high?
Exelixis' current Return-on-Tangible-Asset of 34.26% is 144% above median its 10-year median of 14.04. Based on the distribution chart, Exelixis ranks #39 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Return-on-Tangible-Asset compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #39 out of 1415 companies for Return-on-Tangible-Asset. This places Exelixis in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Exelixis and its competitors. Exelixis's current Return-on-Tangible-Asset is 34.26%, which is 144% above median its own 10-year median of 14.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current Return-on-Tangible-Asset is 34.26%, which is 144% above median its 10-year median of 14.04. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current Return-on-Tangible-Asset is 34.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (FRA:EX9) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for FRA:EX9:
Return-on-Tangible-Asset: 34.26% (144% above median its 10-year median of 14.04)
GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score
Get the complete analysis for FRA:EX9
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EX9 has been successfully added to your 
